Introduction
Previous studies on viral dynamics during primary HIV-1 subtype B infection [1] [2] [3] [4] [5] [6] [7] [8] [9] showed that soon after infection, peak HIV-1 RNA levels reach 10 5 to 10 8 copies/ml [6, 10, 11] , last approximately 2-3 weeks [2, 3, 12] , and then drop to a median of around 30 000 copies/ml within 4-6 months after infection [1, 5, 7, 8] . The rate of decline [3] and levels [5] of HIV-1 RNA in plasma vary substantially among HIV-infected individuals, and initial clearance of HIV-1 RNA can affect disease progression [9, 13] . HIV-1 dynamics in the early phase of non-B subtype infections are generally similar to the patterns observed during primary HIV-1 subtype B infection, although some subtype-specific differences were reported [14] [15] [16] [17] . HIV-1 subtype C isolates were shown to have transmission efficiency similar to that of other group M HIV-1 viruses, but reduced pathogenic fitness following initial infection [18, 19] .
The risk of HIV-1 transmission is associated with levels of HIV-1 RNA load in plasma and semen [16, [20] [21] [22] [23] [24] [25] [26] . Two reports described incremental increases for HIV-1 RNA load level linked to increased viral transmission. In one study [27] , a 0.5 log 10 increase in viral load correlated with a 40% increase in transmission. In the other study [22] , a 0.74 log 10 increase correlated with a 50% greater risk of viral transmission. Recently, we proposed that HIV-1-infected individuals who maintain high levels of HIV-1 RNA load after seroconversion may be an important target for public health interventions for reducing viral transmission in communities [28] .
The current study addressed two questions: what is the fraction of individuals with sustained high HIV-1 RNA load during primary HIV-1 infection after the viremia peak and how long is the high HIV-1 RNA load maintained during primary HIV-1 infection? Because the highest rates of HIV infection are for subtype C in southern Africa, we chose to study HIV-1 RNA dynamics in 77 participants with primary HIV-1 infection in Gaborone, Botswana (n ¼ 42), and Durban, South Africa (n ¼ 35).
Methods

Study participants
Data from two southern African cohorts were analyzed in this study, from the HIV Pathogenesis Programme Acute Infection Study in Durban, KwaZulu-Natal, South Africa (Durban cohort; n ¼ 35) [29] , and the Tshedimoso Study in Gaborone, Botswana (Botswana cohort; n ¼ 42) [17, 30] . In both cohorts, individuals seeking voluntarily testing and counseling for HIV infection were targeted. Written informed consent was obtained from each participant. The time of seroconversion was estimated based on the laboratory results of HIV-1 RNA test, ELISA test for HIV antibodies, and western blot test, either as the midpoint between the last ELISA-negative and the first ELISA-positive test (n ¼ 35), or according to Fiebig staging [4] (n ¼ 42; see details on Fiebig stage assignment in [31] ). The uncertainty in the estimated time of seroconversion may affect the analysis of viral load and CD4 cell dynamics. The cumulative 95% confidence interval (CI) of Fiebig stages II-IV spans from 7 to 8 days per stage, which provides relatively tight and accurate estimation. In contrast, the cumulative 95% CI for Fiebig stage V is expanded to 83 days, leaving more uncertainty in synchronization of individuals identified within this stage, which is a limitation of the study. A total of 77 study participants with estimated time of seroconversion and measurements of HIV-1 RNA load between 100 and 300 days postseroconversion (p/s) were included in the analysis, including RNA load and CD4 cell counts. Individuals in combined cohorts were followed longitudinally for a median [interquartile range (IQR)] of 573 (226-986) days p/s (pre-HAART data). All study participants were infected by HIV-1 subtype C [17, 29, 32] .
Statistical analysis
Descriptive statistics (mean and accompanying 95% CIs, median and corresponding interquartile range) were presented. Comparisons of continuous outcomes between two groups were based on the Mann-Whitney rank-sum test. Comparisons of time-to-event outcomes between two groups were based on the Gehan-Wilcoxon test. The normality of distribution of HIV-1 RNA load was tested by the Shapiro-Wilk test.
For the purpose of analysis in this study, we coined the term extended high viremics to refer to HIV-infected individuals maintaining mean viral load at least 100 000 (5.0 log 10 ) copies/ml during 100-300 days p/s. HIVinfected individuals with mean viral load less than 100 000 (5.0 log 10 ) copies/ml during 100-300 days were referred to as 'others'. For extended high viremics, we estimated the duration of high viral load in the absence of antiretroviral therapy (ART) using cubic smoothing splines for those with more than five data points, and ordinary least squares regression for those with fewer data points. For individuals with increasing HIV-1 RNA levels, the duration of high viral load was imputed as the time from seroconversion to the last observation prior to ART initiation. Selection biases cannot be completely excluded, although a relatively large number of screened individuals (cumulative total is more than 10 000) implies that selection bias is unlikely to be a major issue.
To describe the procedure for estimating the probability of viral load higher than a threshold over time, we introduce some notation: let T denote the time since seroconversion (in days), Y(t) (log 10 , copies/ml) denote viral load value at time T ¼ t, and s denote a threshold. We assume that Y(t) follows a normal distribution with mean m(t) and variance s 2 . Under this assumption, the probability of viral load higher than a threshold s at time t, Pr(Y(t)!sjt), is equal to F{[m(t)-s]/ s}, where F(Á) is the cumulative distribution function for the standard normal random variable. We estimate m(t) and s using local regression models. CIs for Pr(Y(t)!sjt) were derived using the bootstrap method. All reported P values are two-sided and not adjusted for multiple comparisons.
Results
Extended high viremics: individuals with sustained high HIV-1 RNA load
The cumulative HIV-1 RNA load data are presented in Fig. 1 . The fraction of extended high viremics, HIVinfected individuals who maintained mean viral load of at least 100 000 (5.0 log 10 ) copies/ml after 100 days p/s, in the cohorts was calculated over two overlapping time periods, 100-300 and 200-400 days p/s. The median (IQR) number of viral load measurements per individual was 4 (2-6) for both time intervals.
The distribution of HIV-1 RNA load in the analyzed cohorts during the two time intervals was not normal (Fig. 2) . The normality test (Shapiro-Wilk) failed for both time intervals 100-300 and 200-400 days p/s (P < 0.001 and P ¼ 0.034, respectively) indicating that the viral load data deviated from the pattern expected from a normal distribution. A disproportionately large fraction of extended high viremics was the most likely reason contributing to the nonnormal distribution of HIV-1 RNA load data. Despite individual fluctuations, HIV-1 RNA load in extended high viremics was relatively consistent over time ( Fig. 3 ). This was evident from the predominantly horizontal shape of viral load curves in extended high viremics (dark lines in Fig. 3 ), providing information on the evolution and variance of viral load trajectories during the first year of HIV-1 subtype C infection, including the selected time intervals. The cumulative proportion of extended high viremics was 34% (95% CI 23-44%) during the period 100-300 days p/s and 19% (95% CI 9-29%) over the period 200-400 days p/s. The overall estimates were consistent with proportions of extended high viremics within each cohort: 34% (95% CI 19-50%) in the Durban cohort and 33% (95% CI 19-48%) in the Botswana cohort during the period 100-300 days p/s. 
Duration of the extended high viremia state
In HIV-1 infection, after the initial peak of viremia, HIV-1 RNA load is expected to decline to a steady-state level. To address how long high HIV-1 RNA load is maintained during primary HIV-1 infection, the time individuals maintain HIV-1 RNA load at least 100 000 (5.0 log 10 ) copies/ml was quantified among extended high viremics (!100 days p/s). In addition, the time was computed for a subset of individuals who maintained HIV-1 RNA load at least 100 000 (5.0 log 10 ) copies/ml for more than 200 days p/s. The pre-HAART median (IQR) duration of maintaining HIV-1 RNA load at least 100 000 (5.0 log 10 ) copies/ml among extended high viremics was 271 (188-340) days p/s. For the subset with average viral load at least 100 000 (5.0 log 10 ) copies/ml during the period 200-400 days p/s, the median (IQR) duration was 318 (282-459) days.
Rapid decline of CD4 cells in extended high viremics
HIV-1-infected individuals maintaining viral load at least 100 000 (5.0 log 10 ) copies/ml are likely to experience faster depletion of their CD4 þ T cells. Based on the trajectories of CD4 cell decline among extended high viremics, the time of CD4 cell decline to 250 and 350 cells/ml was measured in two groups, extended high viremics and others. The CD4 cell decline to 250 cells/ml matched the current threshold criteria for eligibility of HIV-infected individuals for initiation of antiretroviral treatment in Botswana and South Africa. The second threshold of CD4 cell decline to 350 cells/ml was chosen because current treatment guidelines generally recommend that HIV-infected patients with a CD4 cell count less than 350 cells/ml should initiate HAART [33, 34] . The extended high viremics had a significantly shorter time to CD4 cell decline to 350 cells/ml (median time: 88 vs. 691 days p/s; P < 0.0001, Gehan-Wilcoxon test) and a significantly shorter time to CD4 cell decline to 250 (median time: 363 vs. 1213 days p/s; P < 0.0001, Gehan-Wilcoxon test). The differences in CD4 cell decline between groups were also supported by the survival Kaplan-Meier analysis (Fig. 4) , indicating a dramatic drop in CD4 cell counts during the period 200-300 days p/s in extended high viremics.
Probability of high viral RNA load in primary HIV-1 subtype C infection
Assuming that the clinically meaningful threshold of viral load affecting HIV transmission is likely to be a continuum between 10 000 and 100 000 copies/ml, we estimated the probability of viral RNA load higher than a threshold in primary HIV-1 subtype C infection over time. In Fig. 5 , we plotted the estimated probabilities and associated 95% CIs for three thresholds: 10 000 (4.0 log 10 ), 50 000 (4.7 log 10 ), and 100 000 (5.0 log 10 ) copies/ ml. At 6 months p/s, the probability of viral RNA load higher than 10 000, 50 000, or 100 000 copies/ml was estimated to be 52% (95% CI 47-57%), 27% (95% CI 23-32%) or 19% (95% CI 16-22%), respectively. At 1 year p/s, the probability of viral RNA load higher than 10 000, 50 000, or 100 000 copies/ml was 46% (95% CI 41-51%), 23% (95% CI 19-27%), or 16% (95% CI 13-19%), respectively.
Discussion
A subset of HIV-1 subtype C-infected individualsextended high viremics -maintains high plasma HIV-1 RNA levels for an extended period of time, and was a primary focus of the current study. Although the fact that few individuals may have high levels of HIV-1 RNA load for a long period of time has been well recognized, the actual proportion of extended high viremics [individuals with HIV-1 RNA load ! 100 000 (5.0 log 10 ) copies/ml over 100 days p/s] in primary HIV-1 subtype C infection has hardly been anticipated. The main finding of this study is that one-third of HIV-1 subtype C-infected individuals have HIV-1 RNA load 100 000 (5.0 log 10 ) copies/ml and higher during the period 100-300 days p/s, and 19% of individuals maintain high levels of HIV-1 RNA load during the period 200-400 days p/s.
The current analysis was based on cumulative data from two primary HIV-1 subtype C infection cohorts from southern Africa where the epidemic is most severe. Despite a few predictable differences, the two analyzed cohorts demonstrated remarkable similarity in evolution of HIV-1 RNA load and CD4 þ T-cell counts over time. Merging data from the two cohorts solidified the results due to the increased sample size.
A relatively large proportion of extended high viremics was not likely due to over-representation of symptomatic patients because identification and enrollment of study participants were not based on symptoms in both cohorts. A comparative analysis of the two cohorts provided evidence that the observed pattern of extended high viremics is common in primary HIV-1 subtype C infection. A high proportion of HIV-1 subtype Cinfected individuals with high levels of viral RNA load for extended periods of time could contribute disproportionately to the high prevalence of HIV infection in southern Africa. Such extended high viremics seem particularly appropriate for emphasis using interventions described as Treatment-for-Prevention.
The trajectories of CD4 cell decline among extended high viremics provide evidence that the majority of individuals with longlasting high HIV-1 RNA load are likely to be fast progressors. As is evident from Fig. 4 , a dramatic decline of CD4 þ cells occurred in extended high viremics during the first year of HIV-1 subtype C infection. Such a predictable CD4 cell drop provides a rationale for initiation of early HAART in extended high viremics and leaves little reason for waiting when individuals with high viral HIV-1 RNA load reach the threshold of CD4 cell count. The 6-month interval of CD4 cell testing, which is common practice in many countries, may be inadequate for extended high viremics due to the fast decline of their CD4 þ cell counts, potentially compromising their immune systems substantially. Therefore, public health strategies for initiation of HAART might differ between extended high viremics (e.g., the HIV-1 RNA load-based approach) and others (e.g., the currently used approach focusing on CD4 cell decline).
Although the reasons for maintenance of high viral load in the subset of studied populations are still unidentified, it is likely that viral replicative fitness upon transmission is the major factor contributing to the existence of extended high viremics. For example, HIV-1 transmission between genetically similar hosts might provide a favorable environment for advanced replication of the virus adapted to the previous host, which could result in high HIV-1 RNA levels for an extended period of time. To address this important issue, further dedicated studies are warranted.
A comprehensive analysis of immune responses in the context of host genetics and evolution of viral quasispecies may shed light on potential reason(s) for the existence of extended high viremics and is likely to reveal the underlying mechanisms. To keep the study focused on extended high viremics, immunological analysis was not included in the scope of the current study, which is one of the study limitations.
It would be tempting to compare the extended high viremics infected with HIV-1 subtype C with the well documented patterns during the early phase of HIV-1 subtype B infection. However, we prefer to avoid a direct comparison due to a lack of comparable data between the epidemics caused by subtypes B and C, which to some extent limits generalization of our findings, at least until similar analyses are performed by others. First, there are important differences between the modes of viral transmission (e.g., heterosexual adults vs. MSM). Second, there is a substantial diversity between the genetics of targeted populations that has been made even more apparent by recent genome-wide association studies (GWASs). Third, HIV-1 subtype differences and viral evolution on the population level should be adequately adjusted by relevant host immune responses. It would be important to (re-)analyze the existing data from the early HIV-1 subtype B studies in the context of extended high viremics. In this study, we tried to avoid a simplified comparison between HIV-1 subtypes that could be misleading and/or erroneous without a bold and sophisticated approach.
Due to the nature of the analyzed cohorts, information regarding source partners was not available, creating another study limitation. It would be important to track the changes in viral replicative capacity upon transmission to a new host and to address potential associations between viral replicative capacity and maintenance of high plasma HIV-1 RNA load for an extended period of time in future studies. The relatively short time of followup limited the study's ability to track the rate of disease outcomes.
The role of extended high viremics in viral transmission is likely to be large, although the current study was not powered to address this question. Extended high viremics may fuel the HIV/AIDS epidemic. A strong association between levels of HIV-1 RNA load and viral transmission is evident from previous studies [16, [20] [21] [22] [23] [24] [25] 27, 35] . Maintaining high viral load for an extended period of time increases the probability of HIV-1 transmission. Extended high viremics with unknown HIV status might represent the highest risk group for viral transmission. Therefore, a public health strategy aiming at proactive HIV testing and identification of extended high viremics could be a critical part of successful management of the HIV/AIDS epidemic. Introduction of routine plasma HIV-1 RNA testing can help to identify not only individuals with high viremia, but can also improve identification of HIV-infected individuals before seroconversion. The cost-effectiveness and logistical issues related to feasibility of routine viral load testing constitute critical topics that need to be resolved by modeling and translational research in future studies.
Extended high viremics might represent an appropriate target for studying interventions for developing preventive strategies aiming at control of the HIV/AIDS epidemic in communities. Assuming the disproportionate contribution of extended high viremics to new HIV-1 transmissions, successful management of extended high viremics could provide for a valid assessment of efficacy of a variety of behavioral and biomedical intervention studies. Focusing on a subset of extended high viremics could help to modify the 'Treatment-for-Prevention' approach and make it more feasible for mitigating the HIV epidemic in appropriate communities [28] .
